Skip to main content

Table 1

From: Superiority of dendritic cell vaccine vs tumor cell vaccine: survival by stratification subsets in MACVAC randomized Phase II trial of patient-specific vaccines utilizing antigens from autologous melanoma tumor cell lines

Stratification

Treatment

# of patients

Median survival in months

3-year overall survival

Measurable

DC-TC

8

17.6

33%

Measurable

TC

9

6.5

11%

Non-Measurable

DC-TC

10

Not Reached

56%

Non-Measurable

TC

15

31.3

33%

Recurrent Stage III

DC-TC

3

Not Reached

67%

Recurrent Stage III

TC

6

30.3

17%

Stage IV

DC-TC

15

40.4

60%

Stage IV

TC

18

16.9

28%